Songling Xuemaikang capsules for patients with low-to-medium risk hypertension: study protocol for a randomized controlled trial

BACKGROUND: Hypertension is a major risk factor for cardio-cerebrovascular disease. Songling Xuemaikang capsules (SXC), a formulation of Chinese herbal patent medicine, has been used as a complementary medicine with conventional western medicine to treat patients with hypertension since 1994 in main...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yuerong, Guo, Haiyan, Liu, Yue, Wang, Xin, Liang, Jiaqi, Xi, Ruixi, Bai, Ruina, Shi, Dazhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466697/
https://www.ncbi.nlm.nih.gov/pubmed/30987658
http://dx.doi.org/10.1186/s13063-019-3308-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466697/
https://www.ncbi.nlm.nih.gov/pubmed/30987658
http://dx.doi.org/10.1186/s13063-019-3308-5

Ejemplares similares